[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# $otsky

$OTSKY receives FDA approval for Voyxact, a first-in-class treatment for kidney disease. Otsuka Pharmaceuticals also secures Asia-Pacific rights for a new eye disease asset from 4DMT for up to $XXX million.

### About $otsky
$otsky is a digital asset and blockchain project.  

### Engagements: XXX (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$otsky/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$otsky/time-series/interactions.tsv)  
Current Value: XXX  
Daily Average: XXX  
X Week: XXXXX -XX%  
X Month: XXXXXX +2,923%  
X Months: XXXXXX -XX%  
X Year: XXXXXXX +586%  
1-Year High: XXXXXX on 2025-02-03  
1-Year Low: X on 2024-12-26  

Engagements by network (24h):
X: XXX

  
  
### Mentions: X (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$otsky/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$otsky/time-series/posts_active.tsv)  
Current Value: X  
Daily Average: X  
X Week: XX no change  
X Month: XX -XX%  
X Months: XXX +110%  
X Year: XXX +191%  
1-Year High: XX on 2025-10-26  
1-Year Low: X on 2024-12-11  

Mentions by network (24h):
X: XX

  
  
### Creators: X (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$otsky/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$otsky/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning $otsky in the last XX hours which is down XX% from X in the previous XX hours
Daily Average: X  
X Week: X -XX%  
X Month: X -XX%  
X Months: XX +25%  
X Year: XX +100%  
1-Year High: XX on 2025-06-25  
1-Year Low: X on 2024-12-11  

The most influential creators that mention $otsky in the last XX hours

| Creator                                    | Rank | Followers | Posts | Engagements |
| -------                                    | ---- | --------- | ----- | ----------- |
| [@Quantumup1](/creator/twitter/Quantumup1) | X    | XXXXX     | X     | XXX         |

[View More](/list/creators/$otsky/100)
  
  
### Sentiment: XXX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$otsky/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$otsky/time-series/sentiment.tsv)  
Current Value: XXX%  
Daily Average: XX%  
X Week: XXX% no change  
X Month: XXX% no change  
X Months: XXX% no change  
X Year: XXX% +10%  
1-Year High: XXX% on 2025-01-15  
1-Year Low: XX% on 2025-09-12  

Most Supportive Themes:
- Creator Activity Surge: (33%) The number of active creators mentioning $otsky has seen a significant increase, indicating growing interest and participation from content creators.
- Engagement Growth: (33%) While current engagements are low, the 1-year growth of XXX% suggests a strong historical engagement trend for $otsky.
- Mention Volume Increase: (33%) Mentions of $otsky have surged by 1080% month-over-month, pointing to a rapid increase in public discourse and awareness.
  
Most Critical Themes:
  

### Top $otsky Social Posts
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"TD Cowenthe PT on $VERA to $XX from $XX and reiterated at a Buy rating. $TVTX $OTSKY JBIO VRTX ABBV ALNY IONS Here's what TD Cowen had to say: We are increasing our estimated gross annual pricing for ataci' in IgAN to $350K based on new comparator product pricing increasing our PT to $XX based on higher peak US sales of $1.64B in 2033. Mgmt said Ph2 ataci' PIONEER IgAN/pMN/FSGS-data may come in 1Q26. VERA may pursue a monthly sNDA path as the formulation is the same as weekly. A June/July PDUFA is likely for weekly dosing in IgAN"  
[X Link](https://x.com/Quantumup1/status/1996959648734237017) [@Quantumup1](/creator/x/Quantumup1) 2025-12-05T15:07Z 3919 followers, 1333 engagements


"Raymond James reiterated $VERA Strong Buy/$73 $OTSKY $TVTX JBIO VRTX ABBV ALNY IONS Raymond James said in its note: Pricing data for atacicept's competitor in the IgAN space sibeprenlimab (Voyxact) has been disclosed and it's at the top of the range we have been hearing (if not higher) from buyside investors over the last several weeks. The $30K per Q4W treatment WAC price ($390K annualized WAC assuming XX treatments per year) is roughly double the pricing assumption in our model for atacicept ($195K annualized WAC) which now looks almost absurdly conservative. Given the broad label Voyxact"  
[X Link](https://x.com/Quantumup1/status/1995963371083186594) [@Quantumup1](/creator/x/Quantumup1) 2025-12-02T21:08Z 3919 followers, 3523 engagements


"H.C. Wainwright reiterated $VERA Buy-$90 and saidOn November XX the FDA granted accelerated approval (AA) to sibeprenlimab marketed as Voyxact by Otsuka ( $OTSKY; not rated) for the treatment of adults with primary immunoglobulin A nephropathy (IgAN). $TVTX NVS JBIO VRTX ABBV ALNY IONS H.C. Wainwright addedThis approval was highly anticipated given that sibeprenlimab achieved the primary endpoint of reduction in urine protein creatinine ratio (UPCR) in the ongoing Phase X VISIONARY study. One highlight from sibeprenlimab's AA label is the absence of a UPCR cutoff to define IgAN patients "at"  
[X Link](https://x.com/Quantumup1/status/1994378715053068735) [@Quantumup1](/creator/x/Quantumup1) 2025-11-28T12:11Z 3919 followers, 5209 engagements


"Cantor reit'd $VERA OW-$100/saidWe continue to view VERA shares as undervalued ($1.8B mkt cap with $497M cash as of Sep 30) given the competitive profile in lgAN a multi-$B market that can easily accommodate multiple disease-modifying B cell modulators. $OTSKY $JBIO ALNY ABBV VRTX NVS IONS Cantor additionally said: This view is in line with that of multiple investors we spoke to at ASN who believe IgAN is a $10B market for B-cell modulators. Our math suggests IgAN patients with proteinuria XXX g/day (76% according to literature (here)) represent 85K-151K US patients. Assuming annualized"  
[X Link](https://x.com/Quantumup1/status/1993656292674576894) [@Quantumup1](/creator/x/Quantumup1) 2025-11-26T12:21Z 3919 followers, 10.6K engagements